Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT07570654 is registered in ClinicalTrials.gov with COMPASS Pathways as lead sponsor.

NCT NCT07570654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07570654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Lead sponsor
COMPASS Pathways
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 30, 2026
Completion date
September 30, 2029
Enrollment
300 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

ptsd, ptsd - post traumatic stress disorder, ptsd symptoms, ptsd, post traumatic stress disorder